© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Bausch + Lomb Corporation (BLCO) stock surged +0.12%, trading at $16.11 on NYSE, up from the previous close of $16.09. The stock opened at $16.18, fluctuating between $15.96 and $16.34 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| May 18, 2026 | 16.18 | 16.34 | 15.96 | 16.11 | 407.14K |
| May 15, 2026 | 16.11 | 16.22 | 15.95 | 16.09 | 450.88K |
| May 14, 2026 | 16.41 | 16.41 | 16.11 | 16.27 | 425.34K |
| May 13, 2026 | 15.96 | 16.38 | 15.74 | 16.25 | 624.95K |
| May 12, 2026 | 16.03 | 16.21 | 15.86 | 16.03 | 579.03K |
| May 11, 2026 | 16.16 | 16.32 | 15.96 | 16.03 | 772.85K |
| May 08, 2026 | 15.97 | 16.31 | 15.67 | 16.18 | 587.72K |
| May 07, 2026 | 16.10 | 16.15 | 15.89 | 15.91 | 260.76K |
| May 06, 2026 | 16.20 | 16.20 | 15.82 | 16.00 | 418.76K |
| May 05, 2026 | 16.30 | 16.41 | 15.93 | 16.00 | 348.5K |
| May 04, 2026 | 16.22 | 16.31 | 15.92 | 16.30 | 578.22K |
| Apr 30, 2026 | 15.32 | 15.91 | 15.32 | 15.90 | 704.38K |
| Apr 29, 2026 | 16.07 | 16.39 | 15.26 | 15.34 | 896.12K |
| Apr 28, 2026 | 15.84 | 16.00 | 15.68 | 15.72 | 529.15K |
| Apr 27, 2026 | 15.80 | 16.23 | 15.80 | 15.88 | 425.87K |
| Apr 23, 2026 | 16.06 | 16.06 | 15.62 | 15.78 | 559.63K |
| Apr 22, 2026 | 16.14 | 16.32 | 15.90 | 16.05 | 619.01K |
| Apr 21, 2026 | 16.77 | 16.83 | 15.96 | 16.04 | 374.32K |
| Apr 20, 2026 | 16.71 | 16.83 | 16.69 | 16.76 | 219.87K |
| Apr 17, 2026 | 16.94 | 17.12 | 16.74 | 16.82 | 410.51K |
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
| Employees | 13500 |
| Beta | 0.58 |
| Sales or Revenue | $4.15B |
| 5Y Sales Change% | 0.13% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Instruments & Supplies |